beraprost

Known as: 4-(1,2,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyloct-6-yne-1-enyl)-5-cyclopenta(b)benzofuranyl)butyrate, 1H-Cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-, monosodium salt, 2-Hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2,3,3a,8b-tetrahydro-1H-cyclopenta(b)benzofuran-5-butanoic Acid 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Lipid mediators are emerging as important regulators of the immune system. Based on our previous result that shows strong… (More)
Is this relevant?
2009
2009
We previously showed that an increase in the peroxisome proliferator-activated receptor-delta (PPARdelta), together with… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2008
Review
2008
Prostacyclin and its analogues (prostanoids) are potent vasodilators and possess antithrombotic, antiproliferative and anti… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
2008
2008
Prostacyclin (PGI2) has been shown to inhibit proliferation in vascular smooth muscle cells. To clarify the underlying molecular… (More)
Is this relevant?
2005
2005
Although sildenafil, an oral phosphodiesterase type-5 inhibitor, may offer benefits in the pharmacological management of… (More)
Is this relevant?
2004
2004
Sildenafil, an oral phosphodiesterase type-5 inhibitor, has vasodilatory effects through a cyclic guanosine 3', 5'-monophosphate… (More)
Is this relevant?
2001
2001
OBJECTIVE To evaluate the effects of one year's treatment with beraprost, an orally active prostacyclin analogue, in patients… (More)
  • table 1
  • table 2
  • table 3
  • figure 2
  • figure 1
Is this relevant?
2001
2001
The present study was aimed to elucidate the cellular pathway(s) controlling vascular relaxation triggered by stimulation of… (More)
  • table 1
  • table 2
  • figure 4
  • figure 6
Is this relevant?
1999
1999
We evaluated the inhibitory effects of beraprost, a stable prostacyclin analogue, on platelet aggregation, assessed by two… (More)
Is this relevant?
1996
1996
In 4 patients with primary pulmonary hypertension, there was a -24% +/- 20% decrease in pulmonary vascular resistance, a… (More)
Is this relevant?